Ventricular remodeling

The appropriate surrogate end point for cell-based therapy?

Shahab Ghafghazi, Marcin Wysoczynski, Matthew C L Keith, Joseph B. Moore, Roberto Bolli

Research output: Contribution to journalArticle

Abstract

Prevention and reversal of left ventricular (LV) remodeling in ischemic cardiomyopathy are important therapeutic goals because LV remodeling is directly associated with adverse clinical outcomes. Although imaging parameters of remodeling are surrogate markers for clinical outcomes, the optimal surrogate end points in stem cell trials remain unknown. Meta-analyses show a modest beneficial effect on ejection fraction and LV remodeling when using stem cells. Conclusive evidence for cell-based therapies on LV function and structure requires large phase 3 trials. Here, we will review the literature on the significance of LV remodeling relating to clinical end points and remodeling indices as surrogate outcomes in trial design, and summarize the most important clinical trials on cell-based therapy.

Original languageEnglish (US)
Pages (from-to)126-138
Number of pages13
JournalDialogues in Cardiovascular Medicine
Volume20
Issue number2
StatePublished - 2015
Externally publishedYes

Fingerprint

Ventricular Remodeling
Cell- and Tissue-Based Therapy
Biomarkers
Stem Cells
Cardiomyopathies
Left Ventricular Function
Meta-Analysis
Clinical Trials
Therapeutics

Keywords

  • Acute myocardial infarction
  • Ejection fraction
  • Ischemic cardiomyopathy
  • Left ventricular end-diastolic volume
  • Left ventricular end-systolic volume
  • Nonischemic cardiomyopathy
  • Progenitor cell
  • Stem cell
  • Ventricular remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ghafghazi, S., Wysoczynski, M., Keith, M. C. L., Moore, J. B., & Bolli, R. (2015). Ventricular remodeling: The appropriate surrogate end point for cell-based therapy? Dialogues in Cardiovascular Medicine, 20(2), 126-138.

Ventricular remodeling : The appropriate surrogate end point for cell-based therapy? / Ghafghazi, Shahab; Wysoczynski, Marcin; Keith, Matthew C L; Moore, Joseph B.; Bolli, Roberto.

In: Dialogues in Cardiovascular Medicine, Vol. 20, No. 2, 2015, p. 126-138.

Research output: Contribution to journalArticle

Ghafghazi, S, Wysoczynski, M, Keith, MCL, Moore, JB & Bolli, R 2015, 'Ventricular remodeling: The appropriate surrogate end point for cell-based therapy?', Dialogues in Cardiovascular Medicine, vol. 20, no. 2, pp. 126-138.
Ghafghazi S, Wysoczynski M, Keith MCL, Moore JB, Bolli R. Ventricular remodeling: The appropriate surrogate end point for cell-based therapy? Dialogues in Cardiovascular Medicine. 2015;20(2):126-138.
Ghafghazi, Shahab ; Wysoczynski, Marcin ; Keith, Matthew C L ; Moore, Joseph B. ; Bolli, Roberto. / Ventricular remodeling : The appropriate surrogate end point for cell-based therapy?. In: Dialogues in Cardiovascular Medicine. 2015 ; Vol. 20, No. 2. pp. 126-138.
@article{d951c428d60b48b6a90ad84e7f87d769,
title = "Ventricular remodeling: The appropriate surrogate end point for cell-based therapy?",
abstract = "Prevention and reversal of left ventricular (LV) remodeling in ischemic cardiomyopathy are important therapeutic goals because LV remodeling is directly associated with adverse clinical outcomes. Although imaging parameters of remodeling are surrogate markers for clinical outcomes, the optimal surrogate end points in stem cell trials remain unknown. Meta-analyses show a modest beneficial effect on ejection fraction and LV remodeling when using stem cells. Conclusive evidence for cell-based therapies on LV function and structure requires large phase 3 trials. Here, we will review the literature on the significance of LV remodeling relating to clinical end points and remodeling indices as surrogate outcomes in trial design, and summarize the most important clinical trials on cell-based therapy.",
keywords = "Acute myocardial infarction, Ejection fraction, Ischemic cardiomyopathy, Left ventricular end-diastolic volume, Left ventricular end-systolic volume, Nonischemic cardiomyopathy, Progenitor cell, Stem cell, Ventricular remodeling",
author = "Shahab Ghafghazi and Marcin Wysoczynski and Keith, {Matthew C L} and Moore, {Joseph B.} and Roberto Bolli",
year = "2015",
language = "English (US)",
volume = "20",
pages = "126--138",
journal = "Dialogues in Cardiovascular Medicine",
issn = "1272-9949",
publisher = "Servier International",
number = "2",

}

TY - JOUR

T1 - Ventricular remodeling

T2 - The appropriate surrogate end point for cell-based therapy?

AU - Ghafghazi, Shahab

AU - Wysoczynski, Marcin

AU - Keith, Matthew C L

AU - Moore, Joseph B.

AU - Bolli, Roberto

PY - 2015

Y1 - 2015

N2 - Prevention and reversal of left ventricular (LV) remodeling in ischemic cardiomyopathy are important therapeutic goals because LV remodeling is directly associated with adverse clinical outcomes. Although imaging parameters of remodeling are surrogate markers for clinical outcomes, the optimal surrogate end points in stem cell trials remain unknown. Meta-analyses show a modest beneficial effect on ejection fraction and LV remodeling when using stem cells. Conclusive evidence for cell-based therapies on LV function and structure requires large phase 3 trials. Here, we will review the literature on the significance of LV remodeling relating to clinical end points and remodeling indices as surrogate outcomes in trial design, and summarize the most important clinical trials on cell-based therapy.

AB - Prevention and reversal of left ventricular (LV) remodeling in ischemic cardiomyopathy are important therapeutic goals because LV remodeling is directly associated with adverse clinical outcomes. Although imaging parameters of remodeling are surrogate markers for clinical outcomes, the optimal surrogate end points in stem cell trials remain unknown. Meta-analyses show a modest beneficial effect on ejection fraction and LV remodeling when using stem cells. Conclusive evidence for cell-based therapies on LV function and structure requires large phase 3 trials. Here, we will review the literature on the significance of LV remodeling relating to clinical end points and remodeling indices as surrogate outcomes in trial design, and summarize the most important clinical trials on cell-based therapy.

KW - Acute myocardial infarction

KW - Ejection fraction

KW - Ischemic cardiomyopathy

KW - Left ventricular end-diastolic volume

KW - Left ventricular end-systolic volume

KW - Nonischemic cardiomyopathy

KW - Progenitor cell

KW - Stem cell

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=84941264333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941264333&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 126

EP - 138

JO - Dialogues in Cardiovascular Medicine

JF - Dialogues in Cardiovascular Medicine

SN - 1272-9949

IS - 2

ER -